Mario Tiribelli
YOU?
Author Swipe
View article: Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinib
Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinib Open
Background The response to ruxolitinib after 6 months (RR6) model allows early identification of ruxolitinib‐treated myelofibrosis (MF) patients with poorer overall survival (OS); however, it is less applicable to lower‐risk patients. Meth…
View article: Novel e4a2 BCR∷ABL1 transcript with insertion of CSE1L exons 9 and 10 in a CML patient: a case report
Novel e4a2 BCR∷ABL1 transcript with insertion of CSE1L exons 9 and 10 in a CML patient: a case report Open
The BCR::ABL1 fusion gene, resulting from the Philadelphia (Ph) chromosome, is the defining feature of Chronic Myeloid Leukemia (CML). The fusion transcript typically results from the juxtaposition of ABL1 exons 2 or 3 and BCR exons 1, 13,…
View article: Chronic myeloid leukemia outcomes according to baseline risk and first‐line treatment in real‐world settings: Data from the Italian Network/CML Campus
Chronic myeloid leukemia outcomes according to baseline risk and first‐line treatment in real‐world settings: Data from the Italian Network/CML Campus Open
Background Improved outcome has been reported in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs) in sponsored trials. Methods This is a multicenter prospective cohort study of consecutive patients wit…
View article: Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea
Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea Open
The European LeukemiaNet recently proposed specific Clinical Signs and Symptoms (CSSs) that may trigger cytoreduction in patients with polycythemia vera (PV) at low thrombotic risk (LR). To evaluate the impact of CSSs on the thrombotic ris…
View article: Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter study
Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter study Open
View article: Monoclonal Antibodies Against Myeloid Leukemia Cells: Current Knowledge and Future Directions
Monoclonal Antibodies Against Myeloid Leukemia Cells: Current Knowledge and Future Directions Open
Monoclonal antibodies targeting specific cell surface antigens have emerged as a promising therapeutic approach for acute myeloid leukemia (AML), thus widening the treatment landscape of this heinous disease. These antibodies have been des…
View article: Impact of ELN clinical signs and symptoms on the thrombotic risk in Polycythemia Vera patients treated with front-line hydroxyurea
Impact of ELN clinical signs and symptoms on the thrombotic risk in Polycythemia Vera patients treated with front-line hydroxyurea Open
The European LeukemiaNet recently proposed specific Clinical Signs and Symptoms (CSSs) that should be considered to trigger cytoreduction in patients with polycythemia vera (PV) at low risk (LR) according to conventional criteria (age<60 y…
View article: Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real‐world setting: Interim results of the Italian observational study (ROMEI)
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real‐world setting: Interim results of the Italian observational study (ROMEI) Open
The study investigated ruxolitinib dosing patterns and correlations with clinical outcomes in patients with myelofibrosis from the ROMEI study. Timely and optimal ruxolitinib treatment demonstrated maximum patient benefits such as spleen s…
View article: New Combination Regimens vs. Fludarabine, Cytarabine, and Idarubicin in the Treatment of Intermediate- or Low-Risk Nucleophosmin-1-Mutated Acute Myeloid Leukemia: A Retrospective Analysis from 7 Italian Centers
New Combination Regimens vs. Fludarabine, Cytarabine, and Idarubicin in the Treatment of Intermediate- or Low-Risk Nucleophosmin-1-Mutated Acute Myeloid Leukemia: A Retrospective Analysis from 7 Italian Centers Open
Background: Nucleophosmin-1 (NPM1) mutation accounts for 30% of acute myeloid leukemia (AML) cases and defines either low- or intermediate-risk AML, depending on FLT3-ITD mutation. New combination regimens (NCRs), adding midostaurin and ge…
View article: Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy Open
View article: Cytopenias and Large Splenomegaly are Main Drivers of Poor Outcome after Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis
Cytopenias and Large Splenomegaly are Main Drivers of Poor Outcome after Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis Open
View article: Advancing Chimeric Antigen Receptor T-Cell Therapy for Acute Myeloid Leukemia: Current Limitations and Emerging Strategies
Advancing Chimeric Antigen Receptor T-Cell Therapy for Acute Myeloid Leukemia: Current Limitations and Emerging Strategies Open
Chimeric antigen receptor (CAR) T-cell therapy represents one of the most impressive advances in anticancer therapy of the last decade. While CAR T-cells are gaining ground in various B cell malignancies, their use in acute myeloid leukemi…
View article: Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE study
Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE study Open
View article: The triple A (AAA) model globally recapitulates adverse outcomes in essential thrombocythemia
The triple A (AAA) model globally recapitulates adverse outcomes in essential thrombocythemia Open
View article: Choice of Frontline Tyrosine‐Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A “Campus <scp>CML</scp>” Study
Choice of Frontline Tyrosine‐Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A “Campus <span>CML</span>” Study Open
Objectives The study aimed to evaluate the utilization of frontline TKI therapy in a large cohort of elderly CP‐CML patients. Methods A retrospective analysis was conducted on 332 CP‐CML patients aged 75 years or older among 1929 diagnosed…
View article: Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World Study
Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World Study Open
Background Ruxolitinib (RUX) is a JAK1/2 inhibitor approved for the therapy of myelofibrosis (MF) based on clinical trials including only intermediate2‐high risk (INT2/HIGH) patients. However, RUX is commonly used in intermediate‐1 (INT1) …
View article: Induction therapy for acute myeloid leukemia: still nothing beyond 7+3?
Induction therapy for acute myeloid leukemia: still nothing beyond 7+3? Open
View article: CAR-T Cells in Acute Myeloid Leukemia: Where Do We Stand?
CAR-T Cells in Acute Myeloid Leukemia: Where Do We Stand? Open
Despite recent advances, the prognosis of acute myeloid leukemia (AML) remains unsatisfactory due to disease recurrence and the development of resistance to both conventional and novel therapies. Engineered T cells expressing chimeric anti…
View article: A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements
A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements Open
A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements
View article: The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan Open
The intensification of intermittent TKI therapy is associated with a higher incidence of MR3.0 loss, but those patients who maintain the MR3.0 molecular response at the end of the study have been frequently considered…
View article: ATP-Binding Cassette Subfamily G Member 2 in Acute Myeloid Leukemia: A New Molecular Target?
ATP-Binding Cassette Subfamily G Member 2 in Acute Myeloid Leukemia: A New Molecular Target? Open
Despite the progress in the knowledge of disease pathogenesis and the identification of many molecular markers as potential targets of new therapies, the cure of acute myeloid leukemia remains challenging. Disease recurrence after an initi…
View article: Correction to: Correlation between IPSET‑t risk at diagnosis and subsequent hemorrhage in patients with essential thrombocythemia; a single institution experience
Correction to: Correlation between IPSET‑t risk at diagnosis and subsequent hemorrhage in patients with essential thrombocythemia; a single institution experience Open
View article: Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy Open
Background Anemia is frequently present in patients with myelofibrosis (MF), and it may be exacerbated by treatment with the JAK2 ‐inhibitor ruxolitinib (RUX). Recently, a relevant blast phase (BP) incidence has been reported in anemic MF …
View article: A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis Open
Most patients with myelofibrosis (MF) discontinue ruxolitinib (JAK1/JAK2 inhibitor) in the first 5 years of therapy due to therapy failure. As the therapeutic possibilities of MF are expanding, it is critical to identify patients predispos…
View article: Patient‐reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia
Patient‐reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia Open
Background The authors assessed the clinical utility of patient‐reported symptom monitoring in the setting of newly diagnosed chronic myeloid leukemia (CML). The primary objective was to evaluate adherence to therapy. Methods The authors c…
View article: The Role of Allogeneic Transplantation in Chronic Myeloid Leukemia in 2023: A Case-Based Concise Review
The Role of Allogeneic Transplantation in Chronic Myeloid Leukemia in 2023: A Case-Based Concise Review Open
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML), granting patients a life expectancy close to that of the normal population and, in a subset of patients, the possibility to discontinue …
View article: PB2214: CORRELATION BETWEEN HEMORRHAGIC EVENTS AND IPSET SCORE IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA
PB2214: CORRELATION BETWEEN HEMORRHAGIC EVENTS AND IPSET SCORE IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA Open
Topic: 16. Myeloproliferative neoplasms - Clinical Background: Essential thrombocythemia (ET) course is characterized by increased risk of thrombotic and hemorrhagic events, that represent their leading causes of mortality and morbidity. T…
View article: P549: EFFICACY AND TOXICITY OF CPX-351 IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML): THE MULTICENTER REAL-WORLD EXPERIENCE FROM THE “ITALIAN TRIVENETO REGISTRY”.
P549: EFFICACY AND TOXICITY OF CPX-351 IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML): THE MULTICENTER REAL-WORLD EXPERIENCE FROM THE “ITALIAN TRIVENETO REGISTRY”. Open
Background: CPX-351, a liposomal encapsulation of cytarabine and daunorubicin, has been approved for the treatment of patients with newly diagnosed therapy-related Acute Myeloid Leukemia (t-AML) or AML with myelodisplasia-related changes (…
View article: PB1860: HIGH EFFICACY OF HYPOMETHYLATING AGENTS PLUS VENETOCLAX COMBINATION THERAPY IN ELDERLY PATIENTS AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY: A REAL-LIFE EXPERIENCE.
PB1860: HIGH EFFICACY OF HYPOMETHYLATING AGENTS PLUS VENETOCLAX COMBINATION THERAPY IN ELDERLY PATIENTS AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY: A REAL-LIFE EXPERIENCE. Open
Topic: 4. Acute myeloid leukemia - Clinical Background: The combination therapy with hypomethylating agents (HMAs) decitabine (DAC) or 5-azacitidine (AZA) plus the BCL-2 inhibitor venetoclax (VES) has recently emerged as an effective thera…
View article: P1028: MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX) MONOTHERAPY: PREDICTORS OF EARLY DISCONTINUATION AND DEATH ON TREATMENT. THE SHORT-TERM RUX PROGNOSTIC MODEL (STR-PM)
P1028: MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX) MONOTHERAPY: PREDICTORS OF EARLY DISCONTINUATION AND DEATH ON TREATMENT. THE SHORT-TERM RUX PROGNOSTIC MODEL (STR-PM) Open
Topic: 16. Myeloproliferative neoplasms - Clinical Background: RUX was the first JAK1/2 inhibitor approved for MF patients (pts), with 70% of pts discontinuing within 5 yrs. Recently, the Response to RUX After 6 Months (RR6) model was deve…